The global veterinary dermatology drugs market accounted US$7.8 Bn in 2020 with a significant CAGR of 9.6% during the forecast period of 2021 to 2028.

Veterinary dermatology deals with the expertise in diagnosing and treating various skin disorders in animals such as skin, ear, hair, nail, hoof, and mouth.

Growth Factors

Rising prevalence of diseases among animals results in the growth of global veterinary dermatology drugs market

According to the Food and Agriculture Organization (FAO), lumpy skin disease (LSD) is an economically significant cattle disease that can cause persistent weakness in infected livestock as compared to that caused by foot-and-mouth disease (FMD). Mortality rates of up to 40% or more have been reported, with severe and permanent damage to hides resulting in skin lesions. Lesions in the mouth, pharynx and respiratory tract are common, resulting in rapid deterioration and, in some cases, severe emaciation that can last for months. There is currently no specific antiviral treatment available for LSD infection in cattle. However, two vaccines for Neethling and Kenya sheep and goat pox virus have been widely used in Africa and have achieved great success in the global market. The aforementioned factors have become critical for the expansion of the global veterinary dermatology drugs market.

Report coverage

Market	Veterinary Dermatology Drugs Market
Analysis Period	2017 - 2028
Base Year	2020
Forecast Data	2021 - 2028
Segments Covered	By Animal Type, By Route of Administration, By Indication, By Distribution Channel, and By Geography
Regional Scope	North America, Europe, Asia Pacific, Latin America, and Middle East & Africa
Key Companies Profiled	Elanco Animal Health, Vetoquinol SA, Ceva,  Intervet Inc., a subsidiary of Merck & Co. Inc., Zoetis, Virbac,  Bimeda, Inc., Vivaldis, and among others.
Report Coverage	Market Trends, Drivers, Restraints, Competitive Analysis, Player Profiling, Regulation Analysis
Customization Scope	10 hrs of free customization and expert consultation

Rising pet owners resulting in fuelling pet care decisions propel the growth of global market

According to the 2019-2020 National Pet Owners Survey conducted by the American Pet Products Association, 67% of US households, or approximately 85 million families, own a pet, according to the Insurance Information Institute, Inc. report (APPA). This compares to a 56% increase among US households in the first survey, which was conducted in 1988. Furthermore, according to the Insurance Research Council's 2020 Report, nearly one-third (30%) of Americans adopted a pet at the time of COVID-19.  The National Association of Insurance Commissioners (NAIC) established the Pet Insurance Working Group in 2020, with the goal of developing a model law that would create a stronger regulatory framework for pet insurance across the United States. Such factors have a positive impact on the global veterinary dermatology drugs market.

Key trends

The quintessential factors of pet insurance driving all time high veterinary dermatology drugs market

According to the North American Pet Health Insurance Association (NAPHIA), the pet health insurance sector in the United States increased its gross written premiums by 27.5 percent to US$1.9 billion in 2020 from US$1.5 billion in 2019. In 2020, dogs accounted for 83 percent of in-force gross written premiums. According to NAPHIA, the average annual premium for dog insurance in 2020 was US$218 for accident-only coverage, which included care for foreign body ingestion, laceration, motor vehicle accidents, poisoning, and other injuries. The average annual premium for accident and illness insurance was $594, which covered accident-only benefits as well as illnesses such as cancer, infections, digestive problems, and other illnesses.

Market Segmentation

The global veterinary dermatology drugs market is segmented based on animal type, route of administration, indication, and distribution channel. By animal type, the market is split into companion animal and livestock animal. By route of administration, the market is segregated as oral, topical, and injectable. By indication, the market is segmented as parasitic infection, allergic infection, and others. Furthermore, distribution channel is segmented as retail, e-commerce, and hospital pharmacies.

Based on route of administration, oral segment dominated the market accounting maximum share during the analysis period of 2021 to 2028

According to the Hopkins report, combining two drugs already approved by the US Food and Drug Administration (USFDA) for different applications reduces wound healing and significantly reduces scar tissue in mice and rats. Furthermore, dual treatment is a promising technique for accelerating wound healing in animals with skin ulcers, extensive burns, surgical wounds, and battlefield injuries. This is one of the key drivers of segmental growth, which ultimately contributes to the overall veterinary dermatology drugs market.

In terms of indication, the parasitic infection segment contributes to the overall growth of the veterinary dermatology drug market. As parasites are responsible for some of the most serious and well-known zoonotic infectious diseases transmitted from companion animals to humans around the world. Zoonotic parasitic infections, for example, are a major global public and veterinary health issue spread by stray dogs. For the record, dogs were found to be infected with a single genus of intestinal parasites at a rate of 18.7%. These factors have a positive impact on segmental growth, which ultimately contributes to the overall growth of the veterinary dermatology drugs market.

Regional Overview

North America dominates the veterinary dermatology drugs market; Asia Pacific registers fastest growing CAGR during the projected period of 2021 to 2028

Because of the presence of top companies involved in providing valuable treatment, North America holds the dominant share of the veterinary dermatology drugs market. Animal Dermatology Group, Inc. (ADG), for example, is a privately held US veterinary dermatology specialty company with the world's largest group of veterinary dermatology specialists specializing in the diagnosis and treatment of acute and chronic skin conditions in pets. ADG currently has over 38 veterinarians active in clinical care, research, and academic training to advance the field of veterinary dermatology.

Asia Pacific, on the other hand, is expected to have the fastest growing CAGR for the veterinary dermatology drugs market from 2021 to 2028. During the forecast period of 2021 to 2028, the Asia Pacific region's market for veterinary dermatology drugs is expected to grow at a faster rate. This is due to increased awareness of available veterinary treatment options, as well as the hub for manufacturing facilities of veterinary dermatology drug companies like Elanco. This is one of the most important factors influencing the APAC regional market for veterinary dermatology drugs.

Competitive Landscape

The prominent players of the global veterinary dermatology drugs market involve Elanco Animal Health, Vetoquinol SA, Ceva,  Intervet Inc., a subsidiary of Merck & Co. Inc., Zoetis, Virbac,  Bimeda, Inc., Vivaldis, and among others.

Market Segmentation

Market By Animal Type

• Companion Animal
• Livestock Animal

Market By Route of Administration

• Oral
• Topical
• Injectable

Market By Indication

• Parasitic Infections
• Allergic Infections
• Others

Market By Distribution Channel

• Retail
• E-Commerce
• Hospital Pharmacies

Market By Geography

• North America
  • U.S.
  • Canada
• Europe
  • U.K.
  • Germany
  • France
  • Spain
  • Rest of Europe
• Asia-Pacific
  • China
  • Japan
  • India
  • Australia
  • South Korea
  • Rest of Asia-Pacific
• Latin America
  • Brazil 
  • Mexico
  • Rest of Latin America
• Middle East & Africa
  • GCC
  • South Africa
  • Rest of Middle East & Africa

TABLE OF CONTENT